Essentials of public health management / by Fallon, L. Fleming, Zgodzinski, Eric J.

Essentials of public health management / by Fallon, L. Fleming, Zgodzinski, Eric J.

Human resource management in health care : principles and practice / by 453728 Fallon, L. Fleming, McConnell, Charles R.

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis by Dougados, M, Taylor, P, Bingham III, CO, Fallon, L, Brault, Y, Roychoudhury, S, Wang, L, Kessouri, M

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo by Gladman, DD, Coates, LC, Wu, J, Fallon, L, Bacci, ED, Cappelleri, JC, Bushmakin, AG, Helliwell, PS

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib by Coates, L, Bushmakin, AG, FitzGerald, O, Gladman, DD, Fallon, L, Cappelleri, JC, Hsu, MA, Helliwell, PS

Identifying mediators of pain reduction in patients with psoriatic arthritis treated with tofacitinib: Role of inflammation associated with peripheral arthritis, enthesitis and ski... by Taylor, PC, De Vlam, K, Bushmakin, AG, Fallon, L, Merola, JF, Cappelleri, JC, Hsu, MA, Mease, PJ

Patient perception of medical care for psoriatic arthritis in North America and Europe: results from a global patient survey by Richette, P, Coates, LC, Azevedo, VF, Cappelleri, JC, Moser, J, Queiro-Silva, R, Fallon, L, Kessouri, M

The effect of tofacitinib on residual pain in patients with psoriatic arthritis by Dougados, M, van der Heijde, D, Bingham, CO, Taylor, PC, Fallon, L, Woolcott, J, Brault, Y, Wang, L, Kessouri, M

Understanding mediators of pain reduction in psoriatic arthritis patients treated with tofacitinib: role of inflammation by Taylor, P, Mease, P, Bushmakin, A, Cappelleri, J, Fleischmann, R, Fallon, L, Woolcott, J, Ogdie, A, Azevedo, V, De Vlam, K

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib by de Vlam, K, Ogdie, A, Bushmakin, AG, Cappelleri, JC, Fleischmann, R, Taylor, PC, Azevedo, V, Fallon, L, Woolcott, J, Mease, PJ

Post-marketing safety surveillance of tofacitinib over 9 years in patients with psoriatic arthritis and rheumatoid arthritis by Burmester, GR, Coates, LC, Cohen, SB, Tanaka, Y, Vranic, I, Nagy, E, Lazariciu, I, Chen, A-S, Kwok, K, Fallon, L, Kinch, C

Median time to pain improvement in patients with psoriatic arthritis treated with tofacitinib by de Vlam, K, Ogdie, A, Bushmakin, A, Cappelleri, J, Fleischmann, R, Taylor, P, Azevedo, V, Fallon, L, Maniccia, A, Woolcott, J, Mease, P

Identifying and quantifying the role of inflammation in pain reduction for patients with psoriatic arthritis treated with tofacitinib: a mediation analysis by de Vlam, K, Mease, PJ, Bushmakin, AG, Fleischmann, R, Ogdie, A, Azevedo, VF, Merola, JF, Woolcott, J, Cappelleri, JC, Fallon, L, Taylor, PC

Baseline pain severity as a predictor of pain improvement following treatment with tofacitinib in psoriatic arthritis by Ogdie, A, de Vlam, K, Bushmakin, A, Cappelleri, J, Mease, P, Fleischmann, R, Taylor, P, Azevedo, V, Fallon, L, Maniccia, A, Woolcott, J

Safety and efficacy of Tofacitinib, an oral Janus Kinase inhibitor, up to 36 Months in patients with active Psoriatic Arthritis: data from the third interim analysis of OPAL balanc... by Nash, P, Coates, L, Kivitz, A, Mease, P, Gladman, D, Covarrubias-Cobos, J, Fleishaker, D, Wang, C, Kudlacz, E, Menon, S, Fallon, L, Hendrikx, T, Kanik, K

Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balanc... by Nash, P, Coates, L, Kivitz, A, Mease, P, Gladman, D, Covarrubias-Cobos, J, Fleishaker, D, Wang, C, Kudlacz, E, Menon, S, Fallon, L, Hendrikx, T, Kanik, K

Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire by Coates, LC, Orbai, A-M, Azevedo, VF, Cappelleri, JC, Steinberg, K, Lippe, R, Lim, I, Eder, L, Richette, P, Weng, MY, Queiro Silva, R, Fallon, L

Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study by Nash, P, Coates, LC, Fleishaker, D, Kivitz, AJ, Mease, PJ, Gladman, DD, FitzGerald, O, Wang, C, Wu, J, Hsu, M-A, Menon, S, Fallon, L, Kanik, KS

Treatment modes in rheumatoid arthritis: factors influencing patient preference by Taylor, P, Betteridge, N, Brown, T, Woolcott, J, Kivitz, A, Zerbini, C, Whalley, D, Olayinka-Amao, O, Chen, C, Dahl, P, Ponce de Leon, D, Gruben, D, Fallon, L